China Pharma Holdings, Inc. logo

China Pharma Holdings, Inc.

CPHI

AMEXHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$0.98

−$0.08 · -7.55%

Aug 21, 4:00 PM ET

CPHI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

24

Weakening

Sentiment

52

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Zhilin Li
Listed since
Apr 17, 2002
Employees
215

Market position

Day range

Current $0.98

52-week range

Current $0.98

Open
$1.031
Previous close
$1.06
Volume
275.43K
0.06× average
Average volume
4.44M
Average daily volume
Market cap
39.71M USD
Beta
1.07
Market reference 1
50-day average
$1.1114
-11.82% below average
200-day average
$1.0096
-2.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.73M USD
EV / EBITDA
-5.8×
Earnings yield
-61.39%
Free cash flow yield
0.21%

Profitability & efficiency

Return on equity
-14.02%
Return on assets
-10.28%
Return on invested capital
-11.28%

Financial health

Current ratio
0.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends14%-29%-72%-115%Gross margin, FY2021: 3.62%Gross margin, FY2022: -6.09%Gross margin, FY2023: -4.01%Gross margin, FY2024: -43.84%Gross margin, FY2025: -3.18%Operating margin, FY2021: -29.67%Operating margin, FY2022: -43.79%Operating margin, FY2023: -39.25%Operating margin, FY2024: -101.32%Operating margin, FY2025: -74.53%Net margin, FY2021: -35.26%Net margin, FY2022: -49.02%Net margin, FY2023: -43.91%Net margin, FY2024: -104.58%Net margin, FY2025: -76.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 3.62%. Gross margin FY2022 -6.09%. Gross margin FY2023 -4.01%. Gross margin FY2024 -43.84%. Gross margin FY2025 -3.18%. Operating margin FY2021 -29.67%. Operating margin FY2022 -43.79%. Operating margin FY2023 -39.25%. Operating margin FY2024 -101.32%. Operating margin FY2025 -74.53%. Net margin FY2021 -35.26%. Net margin FY2022 -49.02%. Net margin FY2023 -43.91%. Net margin FY2024 -104.58%. Net margin FY2025 -76.91%.

Income trends

Revenue

4.14M USD-8.49%

Operating income

−3.09M USD+32.69%

Net income

−3.19M USD+32.70%
Income trends across reported periods11.08M USD5.33M USD−422.88K USD−6.17M USDRevenue, FY2021: 9.64M USDRevenue, FY2022: 8.1M USDRevenue, FY2023: 7.01M USDRevenue, FY2024: 4.53M USDRevenue, FY2025: 4.14M USDOperating income, FY2021: −2.86M USDOperating income, FY2022: −3.55M USDOperating income, FY2023: −2.75M USDOperating income, FY2024: −4.59M USDOperating income, FY2025: −3.09M USDNet income, FY2021: −3.4M USDNet income, FY2022: −3.97M USDNet income, FY2023: −3.08M USDNet income, FY2024: −4.74M USDNet income, FY2025: −3.19M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.64M USD. Revenue FY2022 8.1M USD. Revenue FY2023 7.01M USD. Revenue FY2024 4.53M USD. Revenue FY2025 4.14M USD. Operating income FY2021 −2.86M USD. Operating income FY2022 −3.55M USD. Operating income FY2023 −2.75M USD. Operating income FY2024 −4.59M USD. Operating income FY2025 −3.09M USD. Net income FY2021 −3.4M USD. Net income FY2022 −3.97M USD. Net income FY2023 −3.08M USD. Net income FY2024 −4.74M USD. Net income FY2025 −3.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.14M USD4.53M USD7.01M USD8.1M USD9.64M USD
Cost of goods sold4.28M USD6.51M USD7.29M USD8.6M USD9.29M USD
Gross profit−131.95K USD−1.99M USD−281.09K USD−493.92K USD349.27K USD
Research and development280.9K USD283.94K USD240.08K USD185.86K USD318.96K USD
Selling, general, and administrative2.83M USD2.31M USD2.25M USD2.96M USD3.15M USD
Operating expenses2.96M USD2.6M USD2.47M USD3.06M USD3.21M USD
Interest income2K USD6.64K USD6.6K USD10.76K USD3.04K USD
Interest expense102.04K USD154.14K USD333.6K USD434.62K USD542K USD
Depreciation and amortization1.58M USD2.62M USD2.75M USD2.7M USD3.09M USD
Operating income−3.09M USD−4.59M USD−2.75M USD−3.55M USD−2.86M USD
Net income−3.19M USD−4.74M USD−3.08M USD−3.97M USD−3.4M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.04

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.03-0.24-0.44-0.64Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26Q2 '26Q3 '26
Q4 2024, reported Nov 13, 2024: actual -0.6, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual -0.5, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -0.24, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual -0.16, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual -0.17, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 1, 2026: actual -0.18, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -0.04, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -0.04, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.28M1.09M896.46K707.18KQ4 '24No estimateQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25MetQ2 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 13, 2024: actual 1.1M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 1.13M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 1.14M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 1.03M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual 756.22K USD, estimate 756.22K USD, surprise 0.00%, Met estimate. Q2 2026, reported Apr 1, 2026: actual 1.23M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 983.54K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 948.34K USD, estimate —, surprise —, Comparison unavailable.

CPHI news

CPHI peers

Continue in GoAI

Research CPHI

research.disclaimer